MedPath

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Completed
Conditions
Breast Cancer
Registration Number
NCT00090974
Lead Sponsor
Eastern Cooperative Oncology Group
Brief Summary

RATIONALE: Quality-of-life assessment in postmenopausal women who are receiving hormone therapy for breast cancer may help to determine the effects of treatment on these patients and may improve the quality of life for future breast cancer patients.

PURPOSE: This clinical trial is studying quality of life of postmenopausal women who are receiving either exemestane or anastrozole with or without celecoxib for stage I, stage II, or stage IIIA primary breast cancer.

Detailed Description

OBJECTIVES:

Primary

* Compare treatment-related symptoms using the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire in postmenopausal women with receptor-positive stage I, II, or IIIA primary breast cancer undergoing treatment with exemestane vs anastrozole with or without celecoxib on protocol CAN-NCIC-MA27.

Secondary

* Compare health-related quality of life using the FACT-ES questionnaire in patients treated with these regimens.

* Determine the extent to which differences in treatment-emergent symptoms affect overall quality of life in patients treated with these regimens.

OUTLINE: This is a multicenter, companion study. Patients receive treatment on CAN-NCIC-MA27.

Health-related quality of life and treatment-related symptoms are assessed using the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire at baseline and at 3, 6, 12, and 24 months.

PROJECTED ACCRUAL: A total of 1,253 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (224)

Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

🇺🇸

Fairbanks, Alaska, United States

Banner Good Samaritan Medical Center

🇺🇸

Phoenix, Arizona, United States

CCOP - Western Regional, Arizona

🇺🇸

Phoenix, Arizona, United States

Banner Thunderbird Medical Center

🇺🇸

Phoenix, Arizona, United States

North Bay Cancer Center

🇺🇸

Fairfield, California, United States

Glendale Memorial Hospital Comprehensive Cancer Center

🇺🇸

Glendale, California, United States

Memorial Medical Center Cancer Services

🇺🇸

Modesto, California, United States

Comprehensive Cancer Center at Desert Regional Medical Center

🇺🇸

Palm Springs, California, United States

Front Range Cancer Specialists

🇺🇸

Fort Collins, Colorado, United States

Poudre Valley Hospital

🇺🇸

Fort Collins, Colorado, United States

Scroll for more (214 remaining)
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
🇺🇸Fairbanks, Alaska, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.